Objective: We investigated the potentiating effect of U-46619, a synthetic analogue of thromboxane A (TXA ), on the adrenergic These effects are independent of calcium entry through dihydropyridine calcium channels.
Introduction
. However, the mechanisms involved in the enhancement of adrenergic responses by TXA receptor activation 2 Thromboxane A (TXA ) is a cyclooxygenase metaboare not known. We reasoned that U-46619 could modulate 2 2 lite that has been reported to modulate sympathetic neuroadrenergic responses through stimulation of the same transmission in several preparations. U-46619, a synthetic, receptor sites that induce smooth muscle contraction. This metabolically stable analogue of thromboxane A [1] , might have important implications in our understanding of 2 enhances sympathetic neurotransmission in human isolated the detrimental effects associated with acute ischemic urinary bladder [2] , rabbit mesenteric artery [3] and portal syndromes after autologous grafts in the arterial circulation vein [4] , and the pressor response to nerve stimulation in or coronary bypass surgery [7] [8] [9] . Therefore, we designed rat isolated kidney [5] . With regard to human vessels, this study to determine the influence of concentrations of preliminary experiments have shown that low concen-U-46619 within a range which, while having no direct trations of U-46619 enhance contractions elicited by contractile effects, could amplify adrenergic-mediated consympathetic nerve stimulation in human saphenous veins tractions of human saphenous veins. Because previous studies have indicated that U-46619 stimulates the opening 21 21 of voltage-dependent Ca channels to increase Ca the cerebral [12] and coronary [13] vasoconstriction caused were allowed to equilibrate for at least 10 min before they
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by synthetic thromboxane analogues, we also examined were incubated with tetrodotoxin (10 mol / l) or prazosin
whether the enhancing effects of TXA on adrenergic (10 mol / l). After 10-15 min incubation with the 2 21 antagonist, a second set of stimulations was performed. In contractions could be mediated by Ca entry through 21 each experiment, a second frequency-response relationdihydropyridine Ca channels.
ship in untreated vein rings was run in parallel.
To study the effects of U-46619 on electrical field stimulation-induced responses, frequency-response rela-2. Methods tionships were determined in a separate group of experiments. After an initial set of stimulations, the vein rings Vein segments were taken from portions of human were consecutively incubated with increasing concentra-
210
saphenous veins of patients undergoing coronary artery tions of U-46619 (10 to 10 mol / l) for 10 min before bypass surgery (35 patients, 24 men and 11 women; age another set of stimulations was given. As a control, four range 52 to 71 years). The study was approved by the consecutive sets of stimulations were given to a group of ethical committee of our institution, and informed consent untreated vein rings at identical intervals. Less than 10% was obtained from each patient before the study. During variability in the magnitude of electrical field stimulationsurgical preparation of the saphenous vein, the dilation induced contractions was observed for a given ring during procedure was avoided. The veins were immediately four consecutive sets of control stimulations. placed in chilled Krebs-Henseleit solution, and rings 3
In another series of experiments, after a first frequencymm long were cut for isometric recording of tension.
response relationship was obtained, the preparations were Two stainless steel L-shaped pins 200 mm in diameter incubated with either the TXA receptor antagonist SQ-
were introduced through the lumen of the vein ring. One 30741 (10 mol / l), the TXA receptor antagonist (10 2 210 pin was fixed to the wall of the organ bath, and the other mol / l) plus U-46619 (10 mol / l), the reuptake blocker Grass polygraph (model 7). Each vein ring was set up in a l) plus U-46619 (10 mol / l). After 10-15 min incuba-4 ml bath that contained modified Krebs-Henseleit solution with the corresponding drugs, a second set of stimulation of the following millimolar composition: NaCl, 115;
tions was then performed. In each group of experiments, KCl, 4.6; MgCl ?6H O, 1.2; CaCl , 2.5; NaHCO , 25; stimulations without any treatment were run in parallel. equilibrated with 95% oxygen and 5% carbon dioxide to (10 -10 mol / l) and KCl (5-100 mmol / l) were degive a pH of 7.3 to 7.4. Temperature was held at 378C.
termined in a cumulative manner. Control (in the absence Resting tension was set to the optimal level for developof U-46619) and experimental (in the presence of Ument of active force [14] . The optimal resting tension was 46619) data were obtained from separate vascular prepara-3 g. The vein rings were allowed to attain a steady level of tions. Another group of vein rings was incubated with the 28 tension during a 2-3 h accommodation period before TXA receptor antagonist SQ-30741 (10 mol / l) plus 2 210 testing. Functional integrity of the endothelium was con-U-46619 (10 mol / l) before exposure to noradrenaline firmed routinely at the beginning of the experiment by the or KCl. mol / l). plus U-46619 (10 mol / l), and the data were compared Electrical field stimulation was provided by a Grass S88 with those obtained from untreated (control) segments. stimulator via two platinum electrodes positioned on each side and parallel to the axis of the vein ring. To assess the nature of the contractile responses and avoid direct stimu-2.1. Drugs lation of the smooth muscle, frequency-response relationships were determined on a group of veins in the presence
The following drugs were used: tetrodotoxin, nifedipine,
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and absence of 10 mol / l tetrodotoxin following proprazosin, noradrenaline hydrochloride, acetylcholine chlocedures previously described [15] . In summary, the protoride, U-46619 [9,11-dideoxy-11a,9a-epoxy-methanoproscol was designed to find the optimal stimulation parametaglandin F , substance P acetate salt (Sigma, St. Princeton, USA) and cocaine chlorhydrate (Abello, Madmin was allowed between stimulations. The preparations rid, Spain). All drugs were dissolved in Krebs-Henseleit solution except nifedipine, which was dissolved initially in ethanol and further diluted in Krebs solution to the proper final concentration. Drugs were added to the organ bath in volumes of less than 70 ml. Stock solutions of the drugs were freshly prepared every day, and kept on ice throughout the experiment.
Data analysis
All values are expressed as mean6S.E.M. Contractions are reported as a percentage of the maximal tension developed by 100 mmol / l of KCl. EC values (con- single value. Therefore, all n values are presented as the number of patients from whom the blood vessels were obtained. For electrical stimulation experiments, in which was due to the release of noradrenaline from perivascular the same veins were stimulated in the absence and adrenergic nerves acting on a-1 adrenoceptors (results not presence of U-46619, a paired t-test was used. Statistical shown). significance was accepted at P , 0.05.
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U-46619 (3310 -10 mol / l) enhanced in a concentration-dependent manner the contractions to electrical stimulation ( Fig. 2A) . This effect was observed at all the 3. Results frequencies used (Fig. 2B ). In the presence of the TXA 2
28
receptor antagonist SQ-30741 (10 mol / l), U-46619 3.
Effects of the thromboxane analogue U-46619
failed to enhance the responses to electrical stimulation (Fig. 2B) . Blockade of neuronal catecholamines reuptake dependent contractions with an EC of 3.7310 mol / l.
50
(10 mol / l) did not change significantly the frequencyThese contractions were endothelium-independent (Fig. 1) .
response curve to electrical stimulation nor did it inhibit
28
The presence of the TXA antagonist SQ-30741 (10 2 the enhancement of neurogenic responses by U-46619 mol / l) induced a parallel rightward shift (about 27-fold) ( Fig. 2C and D) (P , 0.05) of the response to U-46619, but differences in the maximal tensions developed were not significant (P . for U-46619. The a-1 adrenoceptor blocker prazosin (10 U-46619 (10 mol / l) produced a significant potentiamol / l) did not affect the concentration-response curve to tion of the noradrenaline-induced contractions (Fig. 3A) . 3.1310 mol / l) (Fig. 3B) . In addition, the enhancement level, leading to an increased affinity of noradrenaline for of the contractile responses to noradrenaline by U-46619 its receptor. This may be a likely explanation because was identical to that observed in the absence of nifedipine U-46619 increased the contractions to exogenously applied (Fig. 3B) .
Effects of U-46619 on noradrenaline-and KCl-
noradrenaline. However, this suggestion cannot account The contractions to KCl were significantly potentiated entirely for the present observations because contractions 210 by U-46619 (10 mol / l) (Fig. 3C) . The EC of the to KCl, which are mediated by voltage-dependent calcium 50 concentration-response curve changed from 2862 mmol / l channels, were also potentiated by U-46619, an effect (control) to 2162 mmol / l (U-46619) (P , 0.05). The completely reversed by SQ-30741. Thus the potentiating maximal response to KCl was not changed. Previous effects of thromboxane-receptor activation are not re-28 addition of SQ-30741 (10 mol / l) inhibited the potentiastricted to events triggered by a-adrenergic stimulation but tion by U-46619 on the KCl-response curve (EC 52862 seem to reflect a general modification of vascular smooth 50 mmol / l). In the presence of nifedipine, KCl-induced muscle. Thus we also considered the possibility that the contractions were significantly reduced and U-46619 failed enhancing effects of TXA could be due to a facilitation of 2 21 to enhance the constrictor responses to KCl (Fig. 3C ) Ca entry through dihydropyridine-sensitive calcium The antagonistic action of SQ-30741 was specific since channels. Nifedipine did not affect the contractile response it did not inhibit contractions induced by noradrenaline or induced by electrical stimulation. We have previously
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KCl, even at concentrations as high as 10 mol / l (results reported that nifedipine diminished the maximal responses not shown).
to noradrenaline by 25% without changing the EC values 50 [17] . The present results show that nifedipine did not affect the potentiating action of TXA on noradrenaline-and enhance the contractile effects of electrical stimulation and contractions. Other mechanisms of calcium handling such noradrenaline in the human saphenous vein. The potentiatas an increase in inositol phosphate metabolism and / or ing effects occur at U-46619 concentrations substantially increase calcium release from intracellular reservoirs may lower than those required to produce a clear direct be involved in the potentiating effects of U-46619 on contractile response. The thromboxane receptor antagonist adrenergic stimulation [18, 19] . SQ-30741 inhibited the amplifying effects of U-46619 on
In addition, our results show that TXA potentiated KCl 2 electrical stimulation and noradrenaline-induced contraccontractions, an effect completely reversed by thromboxtions in a concentration-dependent manner. The results are ane-receptor blockade. This suggests, in agreement with consistent with the hypothesis that stimulation of TXA previous reports [20] , that thromboxane-receptor stimula-2 receptors in the absence of direct contraction is followed tion may also bring about a facilitation of extracellular 21 21 by enhancement of responses to both endogenous and Ca entry by KCl through voltage-dependent Ca exogenous noradrenaline. channels. It might be conceived that the effects of U-46619 on Thromboxane A has long been involved in platelet 2 electrical stimulation contractions could involve an effect aggregation and vasospasm [21] [22] [23] [24] . Our experiments of adrenergic nerves, leading to release of noradrenaline, show that TXA not only produces a marked constriction 2 or, alternatively, U-46619 could act with noradrenaline at of human saphenous vein but also potentiates contractions postjunctional receptor sites. Because noradrenaline release elicited by electrical stimulation and noradrenaline through was not measured in this study, a contribution of presynapstimulation of specific receptors. This raises the possibility tic facilitating effects cannot be excluded. The fact that the that TXA may act synergistically with the adrenergic 2 concentration-response curve to U-46619 was not modineurotransmitter and contribute to mechanisms involved in fied by prazosin, an a adrenoceptor blocker, suggests that acute ischemic syndromes associated with venous grafts.
1 the action of U-46619 does not involve release of noradThe human saphenous vein can undergo spasm immedirenaline. Additional support comes from experiments in ately after autologous grafts in the arterial circulation or strips of human saphenous vein showing that the thromcoronary bypass surgery [7] [8] [9] . In view of the specificity boxane analogue U-46619 did not modify electricallyand potency of SQ-30741, our results give functional evoked (3H)-noradrenaline release unless it was used at evidence that drugs that antagonize the actions of thromconcentrations higher than 1 mmol / l [16] . The possibility boxane A by blocking its receptors may have potential 2 that U-46619 could block the reuptake of noradrenaline clinical use providing protection against possible increases and therefore enhance the contractile responses is unlikely in TXA levels. Moreover, if the compound is sufficiently 2 because the potentiating effects were still evident in the specific, the effect of endogenous protective mediators
